医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Igenbio Establishes Direct Presence in Japan

2014年05月23日 AM01:46
このエントリーをはてなブックマークに追加


 

CHICAGO

Igenbio, Inc., a Chicago based genome analysis company, announced today the establishment of a representative office in Japan. Igenbio Japan will be promoting and distributing its flagship product, ERGO, the next generation Genome Analysis & Discovery System, to the Japanese market.

“Igenbio, Inc. has been experiencing growth on all fronts. We are excited to turn our attention to the Japanese life sciences market. We believe that our products align with the high-quality genomics and synthetic biology work being done in Japan,” said Vinayak Kapatral, President & CEO of Igenbio, Inc. “Having a Japan-focused and localized web channel supported by our local office will enable us to better serve our customer base in Japan.”

Japan has been a key area of opportunity for Igenbio. Inc, constituting one of the countries most focused on genomic research. “Having a local office will help Igenbio take up a strong position in this important market by showing our commitment to this extremely demanding customer base,” said Igenbio Japan CM Jaffer Hussainee, the newly appointed Country Manager for Igenbio Japan.

About Igenbio

Chicago-based Igenbio, Inc. specializes in research in microbial genomics, biochemistry, and gene expression. Igenbio, Inc. serves a broad customer base across industry, academic and government institutions. ERGO™ integrates proprietary functional genomic data, metabolic reconstructions, expression profiling, and biochemical and microbiological data and tools for genome research. www.igenbio.com, Japanese website: www.igenbio.jp

CONTACT

Igenbio, Inc.
Vinayak Kapatral, Ph.D.
President, CEO
Tel:
(312) 733-8485 Ext 1
Fax: (312) 277-3478
E-mail: vinayak@igenbio.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc